Approved as Quviviq in Japan, daridorexant is being marketed through a partnership between Nxera and Shionogi.

Denifanstat showed tolerability and a favourable safety profile and most TEAEs were mild or moderate.

Q4 2025 Management View CEO Leonard Schleifer reported "fourth quarter total revenue up 3% year-over-year, driven by double-digit net sales growth for 3 of our leading products." Schleifer highlighted ...

Genmab plans to present full results at an upcoming medical meeting.

Sagimet Biosciences dropped 9% after Ascletis Pharma’s Phase 3 Denifanstat safety data focused on tolerability, not new efficacy, spurring investor caution. SGMT’s Denifanstat, a first-in-class FASN ...

– Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva, an anti-CD20 monoclonal antibody designed for enhanced B cell depletion – – Gazyva has the potential to be a ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in the ...

Scancell (SCLP) is a reminder that biotechnology is a long and expensive game as the company limbers up to move its key iSCIB1+ product into phase 3 trials after receiving the all clear from the US ...

Corcept recently suffered a blow after relacorilant was rejected by the FDA for use in Cushing’s syndrome.